IL-33 and IL-33-derived DC-based tumor immunotherapy

참고문헌 (64)

1. Baekkevold, E. S., "Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules", Am. J. Pathol, 163, pp.69~79 (2003)
2. Lefrancais, E., "Mechanisms of IL-33 processing and secretion : differ ences and similarities between IL-1 family members", Eur. Cytokine Netw, 23, pp.120~127 (2012)
3. Schmitz, J., "IL-33, an interleukin-1-like cytokine that signals via the IL-1receptor-related protein ST2 and induces T helper type 2-associated cytokines", Immunity, 23, pp.479~490 (2005)
4. Lefrancais, E., "Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells", Proc. Natl Acad. Sci. USA, 111, pp.15502~15507 (2014)
5. Afferni, C., "The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity", Front. Immunol, 9, pp.2601~ (2018)
6. Miller, A. M., "Role of IL-33 in inflammation and disease", J. Inflamm, 8, pp.22~ (2011)
7. Cayrol, C., "Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33", Nat. Immunol, 19, pp.375~385 (2018)
8. Townsend, M. J., "T1", ST2deficient mice demonstrate the importance of T1, J. Exp. Med, pp.2000, 191[DOI]
9. Palmer, G., "The IL-1 receptor accessory protein(AcP)is required for IL-33signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33", Cytokine, 42, pp.358~364 (2008)
10. Dominguez, D., "IL-33 in Tumor Immunity : Nothing to Sneeze At", Crit. Rev. Immunol, 38, pp.453~470 (2018)
11. Zhang, X., "The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity", Cancer Manag. Res, 12, pp.7527~7537 (2020)
12. Nascimento, D. C., "IL-33 contributes to sepsis-induced long-term immuno suppression by expanding the regulatory T cell population", Nat. Commun, 8, pp.14919~ (2017)
13. Cohen, E. S., "Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation", Nat. Commun, 6, pp.8327~ (2015)
14. Dominguez, D., "Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer", J. Immunol, 198, pp.1365~1375 (2017)
15. Yangngam, S., "High level of interleukin-33 in cancer cells and cancer associated fibroblasts correlates with good prognosis and suppressed migration in cholangiocarcinoma", J. Cancer, 11, pp.6571~6581 (2020)
16. Schiering, C., "The alarmin IL-33 promotes regulatory T-cell function in the intestine", Nature, 513, pp.564~568 (2014)
17. Matta, B. M., "IL-33 is an unconventional Alarmin that stimulates IL-2 secre tion by dendritic cells to selectively expand IL-33R", ST2+ regulatory T cells, 2014, pp.193, 4010~4020
18. Son, J., "Tumor-Infiltrating Regulatory T-cell Accumulation in the Tumor Microenvironment Is Mediated by IL33", ST2 Signaling, 2020, pp.8, 1393~1406
19. Pastille, E., "The IL-33", ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer, 2019, pp.12, 990~1003
20. Li, A., "IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development", Cell Rep, 29, pp.2998~3008 (2019)
21. Hatzioannou, A., "An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion", Nat. Immunol, 21, pp.75~85 (2020)
22. Lv, Y., "Tumor-infiltrating mast cells stimulate ICOS(+)regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression", J. Adv. Res (2023)[DOI]
23. Eissmann, M. F., "IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization", Nat. Commun, 10, pp.2735~ (2019)
24. Dagher, R., "IL-33-ST2 axis regulates myeloid cell differentiation and activa tion enabling effective club cell regeneration", Nat. Commun, 11, pp.4786~ (2020)
25. Andersson, P., "Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis", JCI Insight, 3 (2018)[DOI]
26. Taniguchi, S., "Tumor-initiating cells establish an IL-33-TGF-beta niche sig naling loop to promote cancer progression", Science, 369 (2020)[DOI]
27. Li, Y., "IL-33 facilitates proliferation of colorectal cancer dependent on COX2", PGE2, 2018, pp.37, 196~
28. Zhou, Q., "The reciprocal interaction between tumor cells and activated f ibroblasts mediated by TNF-alpha", IL-33, Oncogene, pp.2020, 39[DOI]
29. Jovanovic, I. P., "Interleukin-33", ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells, 2014, pp.134, 1669~1682
30. Gao, X., "Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells", J. Immunol, 194, pp.438~445 (2015)
31. Kang, M. H., "Discovery of highly immunogenic spleen-resident FCGR3(+)CD103(+) cDC1s differentiated by IL-33-primed ST2(+) basophils", Cell. Mol. Immunol (2023)[DOI]
32. Villarreal, D. O., "Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity", Cancer Res, 74, pp.1789~1800 (2014)
33. Andreone, S., "IL-33 Promotes CD11b", CD18-Mediated Adhesion of Eosino phils to Cancer Cells and Synapse-Polarized Degranulation Leading to Tumor Cell Killing, 2019, pp.11, ~
34. Hollande, C., "Inhibition of the dipeptidyl peptidase DPP4(CD26)reveals IL 33-dependent eosinophil-mediated control of tumor growth", Nat. Immunol, 20, pp.257~264 (2019)
35. Lucarini, V., "IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils", Oncoimmunology, 6, pp.e1317420~ (2017)
36. Andreone, S., "Anti-Tumorigenic Activities of IL-33 : A Mechanistic Insight", Front. Immunol, 11, pp.571593~ (2020)
37. Jin, Z., "IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4(+)and CD8(+)T Cell Responses in Hepatocellular Carcinoma", J. Immunol, 201, pp.3770~3779 (2018)
38. Qin, L., "Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia", Oncotarget, 7, pp.61069~61080 (2016)
39. Moral, J. A., "ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity", Nature, 579, pp.130~135 (2020)
40. Xia, Y., "Endogenous IL-33 exerts CD8(+)T cell antitumor responses over coming pro-tumor effects by regulatory T cells in a colon carcinoma model", Biochem. Biophys. Res. Commun, 518, pp.331~336 (2019)
41. Chen, L., "Tumor-Derived IL33 Promotes Tissue-Resident CD8(+)T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy", Cancer Immunol. Res, 8, pp.1381~1392 (2020)
42. Zhang, J., "IL-33 drives the antitumour effects of dendritic cells via upregu lating CYLD expression in pulmonary adenocarcinoma", Artif. Cells Nanomed. Biotechnol, 47, pp.1335~1341 (2019)
43. Liu, N., "IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells", Cell. Mol. Immunol, 16, pp.644~651 (2019)
44. Xu, L., "IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice", Biotechnol. Lett, 42, pp.1113~1121 (2020)
45. Perez, C. R., "Engineering dendritic cell vaccines to improve cancer immunotherapy", Nat. Commun, 10, pp.5408~ (2019)
46. Miah, M. A., "CISH is induced during DC development and regulates DC mediated CTL activation", Eur. J. Immunol, 42, pp.58~68 (2012)
47. Miah, M. A., "Egr2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity", Eur. J. Immunol, 43, pp.2484~2496 (2013)
48. Ahmed, M. S., "Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy", Oncoimmunology, 4, pp.e984550~ (2015)
49. Roh, S. E., "Junctional adhesion molecules mediate transendothelial migration of dendritic cell vaccine in cancer immu notherapy", Cancer Lett, 434, pp.196~205 (2018)
50. Rank, M. A., "IL-33-activated dendritic cells induce an atypical TH2-type response", J. Allergy Clin. Immunol, 123, pp.1047~1054 (2009)
51. Awate, S., "Mechanisms of action of adjuvants", Front. Immunol, 4, pp.114~ (2013)
52. Sattler, S., "IL-10-producing regulatory B cells induced by IL-33(Breg(IL-33))effectively attenuate mucosal inflammatory responses in the gut", J. Autoimmunity, 50, pp.107~122 (2014)
53. Liew, F. Y., "Interleukin-33 in health and disease", Nat. Rev. Immunol, 16, pp.676~689 (2016)
54. Sakaguchi, M., "Overexpression of REIC", Dkk-3 in normal fibroblasts sup presses tumor growth via induction of interleukin-7, 2009, pp.284, 14236~14244
55. Mbongue, J. C., "The Role of Dendritic Cell Maturation in the Induction of Insulin-Dependent Diabetes Mellitus", Front. Immunol, 8, pp.327~ (2017)
56. Yu, Q., "CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-kappaB pathway", Artif. Cells Nanomed. Biotechnol, 48, pp.137~142 (2020)
57. Peng, Y. Q., "IL-33 receptor expression on myeloid and plasmacytoid den dritic cells after allergen challenge in patients with allergic rhinitis", Int. Immu nopharmacol, 101, pp.108233~ (2021)
58. Gao, Y., "Emerging Effects of IL-33 on COVID-19", Int. J. Mol. Sci, 23 (2022)[DOI]
59. Moro, K., "Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+)lymphoid cells", Nature, 463, pp.540~544 (2010)
60. Bottcher, J. P., "NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control", Cell, 172, pp.1022~1037 (2018)
61. Zhan, Y., "GM-CSF increases cross-presentation and CD103 expression by mouse CD8(+)spleen dendritic cells", Eur. J. Immunol, 41, pp.2585~2595 (2011)
62. Linette, G. P., "On the Twentieth Anniversary of Dendritic Cell Vaccines-Riding the Next Wave", Cancer Res, 82, pp.966~968 (2022)
63. Luo, X. L., "The quest for faithful in vitro models of human dendritic cells types", Mol. Immunol, 123, pp.40~59 (2020)
64. Usero, L., "Feasibility of using monocyte-derived dendritic cells obtained from cryopreserved cells for DC-based vaccines", J. Immunol. Methods, 498, pp.113133~ (2021)

관련 논문AI추천